MSB (ASX) Ann: MSB Presents at Edison Group Global Healthcare Conference

Originally posted by stockrock: ↑

As a few people picked up already, Mesoblast plan to take the CLBP product all the way to market themselves .. which takes away a potential short term partnership annoucement, but if they can fund and execute it.. then retaining the global ex EU/Latin America rights will be exponentially better for shareholders in the longer term.

It is a balancing act with pros and cons when deciding to partner up or go it alone.. partnering up only makes sense if you can't afford to fund the trial and/or do not believe you will be able to fund / market and distribute the product effectively. I thought that because the cash injection from Novartis was not received, that the need to bolster their capital position that it would push them to partner up CLBP, giving up the lion's share of the profits in the longer term (for an upfront cash injection and usually a dilutionary equity stake).

But it seems the scales were not tipped enough for them to budge, and the fact that they got such a favourable FDA outcome (12 month trial, single endpoint)... this second pivotal trial could be a very quick and cheap trial to run, aided by the network that SurgCenter has which will also make marketing and distribution of the product very effective and achievable without a partner.

CHF is a different story, in that they will definitely need a partner to both fund a potential phase 3 trial and market and distribute the product. So once Mesoblast obtains clarity on the next steps (is it another phase 3 trial, or is there an expedited pathway) they will be in a position to land on a partner. So a partner here is not so much a if, but when and who ... but they can't say much yet on the approval pathway until the FDA give them the formal feedback, which I expect to find out by the end of this quarter.

COVID ARDS also sounds like they are moving ahead with and it which can only be the case if the NIH is going to fund this second trial.

It's quite exciting to think that we could have three pivotal phase 3 trials ongoing later this year... with both CLBP and COVID ARDs potentially stopping early for overwhelming efficacy (if the second phase 3 trial results trend like the first phase 3 trial in the sub-groups studied).

But what is probably most interesting is that Silviu said that he hopes to hear positive news from the FDA's review of the Ryoncil data and dossiers over the coming months... that almost sounds to be that the Ryoncil resubmission has been lodged? It wasn't a 'if they accept our resubmission'... it was ' we hope to hear positive news from the FDA's review... we will be preparing to interface with the FDA... ". Maybe we'll get a bit more clarity on this at the quarterly update, but it would be interesting to know if the review clock has been started already.

Expand

@stockrock, agree all very exciting and thank you for your posts over the past few weeks in particular. @TimmyR30 "Silvu don't be a hero" message is one that I do not agree with but can understand why some might feel that. We know what we have to do, we know the period and we know who we want to recruit. We also have a partner in Grünenthal albeit in Europe it is enough. Why dilute further an opportunity. to increase the value of the company by many billions. In many ways it gives me considerable confidence in their assessment of the Company's cash requirements. The board are professionals and while I am critical of the Communication to Shareholders I am confident that they can work this one out. The real question for me would be. If they wanted to find a partner could they? In my view (with that data, the trial already agreed and the p values from previous), very easily.
Regards
Yelrom

No.	Vol.	Price($)
3	43508	$1.00

No.

Vol.

Price($)

43508

$1.00

Price($)	Vol.	No.
$1.01	34138	2

Price($)

Vol.

No.

$1.01

34138

No.	Vol.	Price($)
3	43508	1.000
1	15862	0.995
5	58523	0.990
3	49529	0.985
3	53984	0.980

No.

Vol.

Price($)

43508

1.000

15862

0.995

58523

0.990

49529

0.985

53984

0.980

Price($)	Vol.	No.
1.005	34138	2
1.010	59763	4
1.015	35684	2
1.020	77095	6
1.025	66956	6

Price($)

Vol.

No.

1.005

34138

1.010

59763

1.015

35684

1.020

77095

1.025

66956

(20min delay)
Last $1.00		Change 0.010(1.01%)		Mkt cap ! $1.141B

Open	High	Low	Value	Volume
$1.01	$1.01	94.3¢	$8.618M	8.821M

@stockrock, agree all very exciting and thank you for your posts...

iTech lifts MRE at Eyre Peninsula Graphite Project by 300%

Lindian shares jump on news of low-cost feasibility results for Kangankunde REE project

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ASX Market Update: ASX200 in the red but real estate faring better | 1 June 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News

@stockrock, agree all very exciting and thank you for your posts...

Top Stories

iTech lifts MRE at Eyre Peninsula Graphite Project by 300%

Lindian shares jump on news of low-cost feasibility results for Kangankunde REE project

Has uranium run out of steam? An update on nuclear markets & developments ahead in FY25

Sun Silver gets that drill to thrill feeling from high grade hits at Maverick Spring

ASX Market Update: ASX200 in the red but real estate faring better | 1 June 2024

Featured News

Buyers (Bids)

Sellers (Offers)

Featured News